AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25530011 — intervention group
Group type: EXPERIMENTAL
Intervention: Boysenberry beverage (750 mg polyphenols)
Number of subjects: 25
Study 25530011 — intervention group
Group type: EXPERIMENTAL
Intervention: Apple fiber beverage (7.5 g dietary fiber)
Number of subjects: 25
Study 25530011 — intervention group
Group type: EXPERIMENTAL
Intervention: Boysenberry plus apple fiber beverage (750 mg polyphenols plus 7.5 g dietary fiber)
Number of subjects: 25
Study 25530011 — intervention group
Group type: COMPARATOR
Intervention: Placebo beverage
Number of subjects: 25
Study 25530011 — intervention group
Group type: EXPERIMENTAL
Intervention: Boysenberry juice beverage
Number of subjects: 25
Study 25530011 — intervention group
Group type: EXPERIMENTAL
Intervention: Apple fiber beverage
Number of subjects: 25
Study 25530011 — intervention group
Group type: EXPERIMENTAL
Intervention: Boysenberry juice plus apple fiber beverage
Number of subjects: 25
Study 25146288 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated poliovirus vaccine (IPV)
Number of subjects: 954
Study 25146288 — intervention group
Group type: COMPARATOR
Intervention: No vaccine (Control)
Number of subjects: 954
Study 22520095 — intervention group
Group type: EXPERIMENTAL
Intervention: CTC group (CT cisternography considered before treatment)
Number of subjects: 52
Study 22520095 — intervention group
Group type: COMPARATOR
Intervention: Surgical group (surgery without considering CTC results)
Number of subjects: 52
Study 19201654 — intervention group
Group type: EXPERIMENTAL
Intervention: Natalizumab
Number of subjects: 897
Study 19201654 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 897
Study 16762429 — intervention group
Group type: EXPERIMENTAL
Intervention: Priming effect in mild-AD
Number of subjects: 22
Study 16762429 — intervention group
Group type: COMPARATOR
Intervention: Object identification task performance
Number of subjects: 22
Study 16762429 — intervention group
Group type: COMPARATOR
Intervention: Recall task performance
Number of subjects: 22
Study 15319041 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard care plus video conferencing/Internet access
Number of subjects: 53
Study 15319041 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard care plus physiological monitoring
Number of subjects: 53
Study 15319041 — intervention group
Group type: COMPARATOR
Intervention: Standard home health care (HHC)
Number of subjects: 53
Study 14727868 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal tretinoin (TRE) and benzoyl peroxide (BP) gels
Number of subjects: 0
Study 14727868 — intervention group
Group type: COMPARATOR
Intervention: Control not specified
Number of subjects: 0
Study 9612233 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRP-2 (1 microgram/kg body wt)
Number of subjects: 7
Study 9612233 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 7
Study 8070509 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral lomefloxacin 200 mg with furosemide 40 mg
Number of subjects: 8
Study 8070509 — intervention group
Group type: COMPARATOR
Intervention: Oral lomefloxacin 200 mg alone
Number of subjects: 8
Study 8070509 — intervention group
Group type: COMPARATOR
Intervention: Furosemide 40 mg alone
Number of subjects: 8
Study 3123119 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete intravenous nutritional support (IVF) with all D‐glucose
Number of subjects: 0
Study 3123119 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete intravenous nutritional support (IVF) with 50% D‐glucose/50% lipid
Number of subjects: 0
Study 3123119 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete intravenous nutritional support (IVF) with D‐glucose/amino acid regimen
Number of subjects: 0
Study 3123119 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete intravenous nutritional support (IVF) with D‐glucose/lipid/amino acid regimen
Number of subjects: 0
Study 30356378 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRH plus arginine test in HD group (9 patients with cardiovascular disease)
Number of subjects: 31
Study 30356378 — intervention group
Group type: COMPARATOR
Intervention: GHRH plus arginine test in non-HD group (12 patients without cardiovascular disease)
Number of subjects: 31
Study 27039058 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone Counseling (TC)
Number of subjects: 168
Study 27039058 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 168
Study 24196555 — intervention group
Group type: EXPERIMENTAL
Intervention: Totally extraperitoneal repair (TEP) under general anesthesia
Number of subjects: 72
Study 24196555 — intervention group
Group type: COMPARATOR
Intervention: Lichtenstein repair under local anesthesia
Number of subjects: 72
Study 21986868 — intervention group
Group type: EXPERIMENTAL
Intervention: ART
Number of subjects: 602
Study 21986868 — intervention group
Group type: COMPARATOR
Intervention: non-ART
Number of subjects: 602
Study 20406831 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant therapy (NT) including epirubicin/cyclophosphamide followed by docetaxel alone, docetaxel with capecitabine, or docetaxel followed by capecitabine, with additional trastuzumab treatment for HER2-positive tumors.
Number of subjects: 213
Study 20406831 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant therapy (NT) with trastuzumab for HER2-positive tumors.
Number of subjects: 213
Study 20406831 — intervention group
Group type: COMPARATOR
Intervention: Neoadjuvant therapy (NT) with no specific control mentioned.
Number of subjects: 213
Study 18242480 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy with carvedilol and amiodarone
Number of subjects: 30
Study 18242480 — intervention group
Group type: COMPARATOR
Intervention: Carvedilol alone
Number of subjects: 30
Study 15168002 — intervention group
Group type: EXPERIMENTAL
Intervention: Transurethral Foley catheter removed postoperatively the next morning (Group A)
Number of subjects: 86
Study 15168002 — intervention group
Group type: COMPARATOR
Intervention: Transurethral indwelling catheter left in place until the fifth postoperative day (Group B)
Number of subjects: 86
Study 11411960 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum NO concentrations measured indirectly in terms of nitrate using colorimetric assay
Number of subjects: 27
Study 11411960 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease activity parameters including C-reactive protein, number of swollen and tender joints, Ritchie articular index, and disease activity scores
Number of subjects: 27
Study 9839852 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine chip in conjunction with scaling and root planing
Number of subjects: 0
Study 9839852 — intervention group
Group type: COMPARATOR
Intervention: Scaling and root planing alone
Number of subjects: 0
Study 8043521 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluphenazine
Number of subjects: 26
Study 8043521 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 26
Study 8043521 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 2903425 — intervention group
Group type: EXPERIMENTAL
Intervention: CV 205‐502 (0.01 to 0.09 mg single oral doses)
Number of subjects: 10
Study 2903425 — intervention group
Group type: EXPERIMENTAL
Intervention: CV 205‐502 (0.06 mg single oral dose)
Number of subjects: 10
Study 2903425 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 30884661 — intervention group
Group type: EXPERIMENTAL
Intervention: Fermented milk with probiotic (Lactobacillus rhamnosus)
Number of subjects: 0
Study 30884661 — intervention group
Group type: COMPARATOR
Intervention: Fermented milk without probiotic (placebo)
Number of subjects: 0
Study 28699551 — intervention group
Group type: EXPERIMENTAL
Intervention: Camino Verde intervention
Number of subjects: 0
Study 26573323 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Enhancement Treatment (MET)
Number of subjects: 1000
Study 26573323 — intervention group
Group type: EXPERIMENTAL
Intervention: MET plus an add-on with eight sessions based on the Community Reinforcement Approach (CRA)
Number of subjects: 1000
Study 26573323 — intervention group
Group type: COMPARATOR
Intervention: Control group (MET only)
Number of subjects: 1000
Study 26573323 — intervention group
Group type: EXPERIMENTAL
Intervention: Total abstinence (secondary outcome)
Number of subjects: 1000
Study 26573323 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life (secondary outcome)
Number of subjects: 1000
Study 26573323 — intervention group
Group type: EXPERIMENTAL
Intervention: Compliance with treatment (secondary outcome)
Number of subjects: 1000
Study 22733239 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine with CYP2D6 genotype 0
Number of subjects: 68
Study 22733239 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine with CYP2D6 genotype 0 plus 1
Number of subjects: 68
Study 21199958 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 0
Study 21199958 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 19638080 — intervention group
Group type: COMPARATOR
Intervention: Medication group (nadolol plus isosorbide‐5‐mononitrate)
Number of subjects: 0
Study 19638080 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined group (banding ligation plus medications)
Number of subjects: 0
Study 19638080 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 0
Study 16857509 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiquadrant cortical cleaving hydrodissection and hydrodelineation (n = 48 eyes)
Number of subjects: 86
Study 16857509 — intervention group
Group type: COMPARATOR
Intervention: No multiquadrant cortical cleaving hydrodissection, only hydrodelineation (n = 38 eyes)
Number of subjects: 86
Study 15108863 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% clindamycin vaginal cream (CVC)
Number of subjects: 404
Study 15108863 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 404
Study 15108863 — intervention group
Group type: EXPERIMENTAL
Intervention: CVC
Number of subjects: 404
Study 11117277 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg/day of lycopene (LYC‐O‐MATO)
Number of subjects: 20
Study 11117277 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 9494599 — intervention group
Group type: EXPERIMENTAL
Intervention: ABVD chemotherapy followed by mediastinal irradiation at a median dose of 36 Gy (range 30.6‐43.2)
Number of subjects: 32
Study 8416243 — intervention group
Group type: EXPERIMENTAL
Intervention: THAM (tromethamine)
Number of subjects: 149
Study 8416243 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 149
Study 3092976 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted management (test practices)
Number of subjects: 60
Study 3092976 — intervention group
Group type: COMPARATOR
Intervention: Control management (control practices)
Number of subjects: 60
Study 30011303 — intervention group
Group type: EXPERIMENTAL
Intervention: Complementary and alternative medicine (CAM) usage
Number of subjects: 1500
Study 30011303 — intervention group
Group type: EXPERIMENTAL
Intervention: Middle subjective social status (structural determinant)
Number of subjects: 1500
Study 30011303 — intervention group
Group type: EXPERIMENTAL
Intervention: Hope (intermediary determinant)
Number of subjects: 1500
Study 30011303 — intervention group
Group type: EXPERIMENTAL
Intervention: Female sex
Number of subjects: 1500
Study 30011303 — intervention group
Group type: EXPERIMENTAL
Intervention: Health anxiety
Number of subjects: 1500
Study 25944813 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg dexketoprofen in 50 ml saline
Number of subjects: 224
Study 25944813 — intervention group
Group type: COMPARATOR
Intervention: 50 ml saline as placebo
Number of subjects: 224
Study 25120329 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminophylline
Number of subjects: 50
Study 23206408 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose Cyclosporine A (trough concentrations 130 < CsA < 200 μg/L, n=47)
Number of subjects: 95
Study 23206408 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose Cyclosporine A (trough concentrations 200 < CsA < 300 μg/L, n=48)
Number of subjects: 95
Study 20933482 — intervention group
Group type: EXPERIMENTAL
Intervention: MD+glucose (2:1 ratio)
Number of subjects: 10
Study 20933482 — intervention group
Group type: EXPERIMENTAL
Intervention: MD+galactose (2:1)
Number of subjects: 10
Study 20933482 — intervention group
Group type: EXPERIMENTAL
Intervention: MD+fructose (2:1)
Number of subjects: 10
Study 18608200 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan
Number of subjects: 9995
Study 18608200 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine
Number of subjects: 9995
Study 18608200 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan (Lowest Quartile)
Number of subjects: 9995
Study 18608200 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine (Lowest Quartile)
Number of subjects: 9995
Study 18608200 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan (Second Quartile)
Number of subjects: 9995
Study 18608200 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine (Second Quartile)
Number of subjects: 9995
Study 18608200 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan (Third Quartile)
Number of subjects: 9995
Study 18608200 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine (Third Quartile)
Number of subjects: 9995
Study 18608200 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan (Fourth Quartile)
Number of subjects: 9995
Study 18608200 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine (Fourth Quartile)
Number of subjects: 9995
Study 18608200 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan vs Amlodipine (Fourth Quartile)
Number of subjects: 9995
Study 18608200 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan vs Amlodipine (Treatment Benefit)
Number of subjects: 9995
Study 15531937 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary Direct Stenting (PDS)
Number of subjects: 100
Study 15531937 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic Atraumatic Coronary Artery Bypass (EACAB)
Number of subjects: 100
Study 10903213 — intervention group
Group type: EXPERIMENTAL
Intervention: Cylexin (CY-1503) administered on the day of surgery
Number of subjects: 51
Study 10903213 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 10903213 — intervention group
Group type: EXPERIMENTAL
Intervention: Cylexin (CY-1503)
Number of subjects: 51
Study 9071250 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-based problem-solving therapy sessions conducted by graduate student therapists supervised by a psychiatrist.
Number of subjects: 29
Study 9071250 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (not specified what intervention was used).
Number of subjects: 29
Study 12959286 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital meal provision plus supplemental feeding with Build-up (Nestle) and Maxijul (SHS Ltd)
Number of subjects: 14
Study 12959286 — intervention group
Group type: COMPARATOR
Intervention: Hospital provision alone
Number of subjects: 14
Study 3530151 — intervention group
Group type: EXPERIMENTAL
Intervention: ECMO in Phase I (50 moribund patients)
Number of subjects: 100
Study 3530151 — intervention group
Group type: COMPARATOR
Intervention: ECMO in Phase II (30 high risk patients)
Number of subjects: 100
Study 3530151 — intervention group
Group type: EXPERIMENTAL
Intervention: ECMO in Phase III (20 moderate to high risk patients)
Number of subjects: 100
Study 3530151 — intervention group
Group type: EXPERIMENTAL
Intervention: ECMO for persistent fetal circulation
Number of subjects: 100
Study 3530151 — intervention group
Group type: EXPERIMENTAL
Intervention: ECMO for congenital diaphragmatic hernia
Number of subjects: 100
Study 3530151 — intervention group
Group type: EXPERIMENTAL
Intervention: ECMO for meconium aspiration
Number of subjects: 100
Study 3530151 — intervention group
Group type: EXPERIMENTAL
Intervention: ECMO for respiratory distress syndrome
Number of subjects: 100
Study 3530151 — intervention group
Group type: EXPERIMENTAL
Intervention: ECMO for sepsis
Number of subjects: 100
Study 3530151 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up outcomes
Number of subjects: 100
Study 30541346 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity interval training (12 weeks, 3 sessions/week)
Number of subjects: 22
Study 30541346 — intervention group
Group type: COMPARATOR
Intervention: Standard care control group
Number of subjects: 22
Study 30541346 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity interval training
Number of subjects: 22
Study 28791976 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetric EvoCeram bulk-fill composite resin
Number of subjects: 34
Study 28791976 — intervention group
Group type: COMPARATOR
Intervention: Universal nano-hybrid resin composite (Tetric EvoCeram)
Number of subjects: 34
Study 27521437 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 484
Study 27521437 — intervention group
Group type: COMPARATOR
Intervention: Gabapentin
Number of subjects: 484
Study 24356922 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral oxycodone plus intravenous acetaminophen
Number of subjects: 153
Study 24356922 — intervention group
Group type: COMPARATOR
Intervention: Intravenous morphine sulfate
Number of subjects: 153
Study 23042034 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin (onabotulinumtoxinA) injection (160 U) into biceps brachii
Number of subjects: 19
Study 23042034 — intervention group
Group type: COMPARATOR
Intervention: Before injection
Number of subjects: 19
Study 19503784 — intervention group
Group type: EXPERIMENTAL
Intervention: Degarelix (240 mg initial dose followed by 80 mg or 160 mg monthly injections)
Number of subjects: 0
Study 19503784 — intervention group
Group type: EXPERIMENTAL
Intervention: Degarelix
Number of subjects: 0
Study 19503784 — intervention group
Group type: COMPARATOR
Intervention: Leuprolide (GnRH agonist)
Number of subjects: 0
Study 17498195 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine
Number of subjects: 52
Study 17498195 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 15471520 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin modified glass ionomer restoration (Vitremer, 3M)
Number of subjects: 83
Study 15471520 — intervention group
Group type: COMPARATOR
Intervention: Amalgam or composite restoration (control)
Number of subjects: 83
Study 11220888 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadropril (6 mg once daily)
Number of subjects: 80
Study 11220888 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine (initially 5 mg/day, increased to 10 mg/day if necessary)
Number of subjects: 80
Study 11220888 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine (5 mg and 10 mg)
Number of subjects: 80
Study 11220888 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadropril
Number of subjects: 80
Study 9750602 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular ephedrine 30 mg immediately after SB
Number of subjects: 20
Study 9750602 — intervention group
Group type: COMPARATOR
Intervention: Placebo (1 mL of intramuscular saline) immediately after SB
Number of subjects: 20
Study 8458358 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 50
Study 8458358 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 50
Study 8458358 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment (Nifedipine + Propranolol)
Number of subjects: 50
Study 8458358 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 8458358 — intervention group
Group type: COMPARATOR
Intervention: Baseline Holter monitoring
Number of subjects: 50
Study 3797826 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of oral nifedipine
Number of subjects: 8
Study 3797826 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 31167860 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass
Number of subjects: 0
Study 31167860 — intervention group
Group type: COMPARATOR
Intervention: Sleeve gastrectomy
Number of subjects: 0
Study 30513108 — intervention group
Group type: EXPERIMENTAL
Intervention: Raltegravir-intensified ART
Number of subjects: 1805
Study 30513108 — intervention group
Group type: COMPARATOR
Intervention: Standard ART
Number of subjects: 1805
Study 27938362 — intervention group
Group type: EXPERIMENTAL
Intervention: ao-dake-humi
Number of subjects: 24
Study 25614338 — intervention group
Group type: COMPARATOR
Intervention: Standard cryoballoon (CB‐S)
Number of subjects: 36
Study 25614338 — intervention group
Group type: EXPERIMENTAL
Intervention: Redesigned cryoballoon Arctic Front Advance (CB‐A)
Number of subjects: 36
Study 25614338 — intervention group
Group type: EXPERIMENTAL
Intervention: Left pulmonary veins (PVs)
Number of subjects: 36
Study 25614338 — intervention group
Group type: EXPERIMENTAL
Intervention: Right pulmonary veins (PVs)
Number of subjects: 36
Study 23940228 — intervention group
Group type: EXPERIMENTAL
Intervention: Project Connect Online (3-hour workshop for hands-on creation of personal Web sites with a follow-up call)
Number of subjects: 88
Study 23940228 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control
Number of subjects: 88
Study 21158876 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcoholics Anonymous (AA) attendance
Number of subjects: 1726
Study 18212722 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Clinical Observation (ACO)
Number of subjects: 105
Study 18212722 — intervention group
Group type: COMPARATOR
Intervention: Outpatient Group (OG)
Number of subjects: 105
Study 16997680 — intervention group
Group type: EXPERIMENTAL
Intervention: Etomidate (0.2 mg/kg)
Number of subjects: 100
Study 16997680 — intervention group
Group type: COMPARATOR
Intervention: Midazolam (0.1 mg/kg)
Number of subjects: 100
Study 14584565 — intervention group
Group type: EXPERIMENTAL
Intervention: FDG-PET imaging
Number of subjects: 12
Study 14584565 — intervention group
Group type: EXPERIMENTAL
Intervention: FDG uptake ratios with occipital lobe metabolism as covariate reference region
Number of subjects: 12
Study 14584565 — intervention group
Group type: EXPERIMENTAL
Intervention: FDG uptake ratios with white matter metabolism as reference covariate
Number of subjects: 12
Study 14584565 — intervention group
Group type: EXPERIMENTAL
Intervention: General analyses
Number of subjects: 12
Study 10712324 — intervention group
Group type: COMPARATOR
Intervention: Intravenous augmentation therapy
Number of subjects: 147